Amivas Inc.

AMIVAS is a US, Australian, and European joint venture focused on the development and commercialization of therapeutics for the treatment of life-threatening diseases with offices in the US, Australia and Ireland. AMIVAS manufactures in North America and our partners in Canada, USA and Europe package and supply our product to hospitals and patients in need. AMIVAS’ vision was formed in response to the urgent need for a US and Europe- based firm to assume responsibility for the manufacture and distribution of Artesunate, for the treatment of severe malaria after quinidine gluconate was discontinued in 2019. With the US Food and Drug Administration (FDA) approval of its first commercial product on May 26, 2020, AMIVAS is proud to join the global effort to fight and eradicate malaria.